BUSINESS

Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage

By Tatsuya Otsuka August 28, 2026

Record-breaking rainfall hit Ishikawa and Toyama prefectures on August 27, prompting the highest-level emergency alert, with some drug deliveries suspended due to poor road conditions even as wholesalers reported no injuries or damage to their facilities.

Jiho contacted five wholesalers operating in the Hokuriku central Japan region, where the prefectures are located, on the same day. Medipal Holdings, Suzuken, Toho Holdings, Alfresa Holdings, which operates in Hokuriku through its Kanazawa-based subsidiary Meisho, and local wholesaler Fines all confirmed no injuries to employees or damage to their business sites.

While most reported no major impact on drug deliveries, Fines had to cancel some of its twice-daily deliveries in the Himi area of Toyama, one of the hardest-hit locations. Some deliveries also could not be made in parts of the Hakui area in Ishikawa.

Partial expressway closures also resulted in some deliveries taking longer than usual.

Heavy rain is forecast to continue in the Hokuriku region through August 28, with wholesalers remaining on alert for further disruption while prioritizing employee safety.

BUSINESS

By Hayate Horiguchi

The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…

By Shunsuke Tani

PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…

By Takashi Ebisawa

Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…

Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…

By Takashi Ebisawa

Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…